CONNECTA Therapeutics

Pioneering first-in-class neuroplasticity modulators for unmet medical needs in CNS disorders

[CONNECTA Therapeutics @ConnectaThx]

We have initiated our Phase IIa clinical trial of #CTH120 in #FragileXSyndrome (FXS)! This marks a major milestone for @ConnectaThx, bringing us one step closer to evaluating its potential as a therapy for a condition with no approved targeted treatments.
#FXS #RareDisease

[CONNECTA Therapeutics @ConnectaThx]

💜 It’s #ChildNeurologyAwarenessDay!

@ConnectaThx is advancing #CTH120, a first-in-class therapy now starting the pediatric development for Fragile X Syndrome (#FXS) supported by the EU-funded #FRAXCURE project.

#ChildNeurology #RareDisease

[CONNECTA Therapeutics @ConnectaThx]

💜 October is #RettSyndromeAwareness Month!

At @ConnectaThx, we stand with the global Rett community and are dedicated to advancing science that tackles the root causes of #RareDisease.

#RettSyndromeAwareness #NeurodevelopmentalDisorders

[CONNECTA Therapeutics @ConnectaThx]

🧠 October is #ADHDAwarenessMonth!

At @ConnectaThx, we’re developing #neuroplasticity modulators that aim to go beyond symptoms and target underlying pathways in #ADHD and other #CNS disorders.

🙏 Thanks @ADHDMonth for shining a light on the many faces of ADHD!

[Catalonia.Health @CataloniaHealth]

NEWS | @VHIR_ and Prous Institute will promote high-impact research projects in the early stages of development 👉 https://t.co/NnAmbRiOD1

[Inveready @inveready]

@ConnectaThx avanza en su programa #CTH120 a fase II en pacientes pediátricos para el síndrome del cromosoma X frágil (SXF), tras completar con éxito la fase I.
#CTH120 es la primera terapia modificadora de la enfermedad para este trastorno neurológico sin tratamiento aprobado.

[@CDTI_innovacion @CDTI_innovacion]

@ConnectaThx , empresa coinvertida por Innvierte, SICC del @CDTI_innovacion, avanza hacia la Fase II del programa #CTH120, desarrollo pediátrico para el tratamiento del Síndrome X Frágil (#SXF), cofinanciado por la Unión Europea en el programa @EUeic Accelerator 👇

[@CDTI_innovacion @CDTI_innovacion]

@ConnectaThx, empresa coinvertida por Innvierte, SICC del @CDTI_innovacion, avanza hacia la Fase II del programa #CTH120, desarrollo pediátrico para el tratamiento del Síndrome X Frágil (#SXF), cofinanciado por la Unión Europea en el programa @EUeic Accelerator 👇

[Catalonia.Health @CataloniaHealth]

NEWS | @ConnectaThx to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome 👉 https://t.co/bXaTQduZte

[CONNECTA Therapeutics @ConnectaThx]

🚀Un gran pas per @ConnectaThx!

#CTH120 avança cap a assajos clínics pediàtrics de Fase II, cofinançat per la UE amb 2,5M€ sota el programa @EUeic Accelerator.

Per més informació sobre la nostra primera teràpia modificadora per #SindromeXFragil👇
https://t.co/E9DIbpLsQw
#EUeic

[CONNECTA Therapeutics @ConnectaThx]

🚀Un gran paso para @ConnectaThx!

#CTH120 avanza a ensayos clínicos pediátricos de Fase II, cofinanciado por la UE con 2,5M€ bajo el programa @EUeic Accelerator.

Más información sobre nuestra primera terapia modificadora para #SindromeXFragil👇
https://t.co/E9DIbpLsQw
#EUeic

[CONNECTA Therapeutics @ConnectaThx]

🚀Big step for @ConnectaThx !

Our lead candidate #CTH120 moves to Phase II pediatric trials, co-funded by the EU with a €2.5M @EUeic Accelerator grant.

Read more about our aim to deliver the first disease-modifying therapy for #FragileXSyndrome👇
https://t.co/E9DIbpLsQw
#EUeic

[Biotech-Spain.com @Biotech_Spain]

. @ConnectaThx announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120 https://t.co/2KfsGhSAwc

[Biotech-Spain.com @Biotech_Spain]

. @ConnectaThx completa el ensayo clínico de Fase I de su fármaco CTH120 para el tratamiento de trastornos del neurodesarrollo https://t.co/mcE2qX361S

[CONNECTA Therapeutics @ConnectaThx]

We are currently conducting an observational study on the biomarkers that will be used in the Phase IIa clinical trial with HMRI, @I3ptT and @CRGenomica.

#FragileXSyndrome #neurology #RareDiseases #OrphanDrug

[CONNECTA Therapeutics @ConnectaThx]

CONNECTA Therapeutics announces positive results from Phase I clinical trial of neurodevelopmental disorders drug candidate CTH120: https://t.co/RyuDaM5Orp

A randomised, double-blind and placebo-controlled study that recruited 76 healthy adults at @HMar_research in Barcelona👇🏼

[CONNECTA Therapeutics @ConnectaThx]

Today, February 28, is World #RareDiseasesDay, a special day to raise awareness on the extraordinary strength and resilience of 300 M people worldwide living with rare diseases.
Video: https://t.co/zi4htkAMsp

[@CDTI_innovacion @CDTI_innovacion]

🔝 España ocupa el 4º lugar en el último corte 2024 del Acelerador #EIC de #HorizonteEuropa 🇪🇺👏

6⃣ empresas españolas de las 71 financiadas
🤝 79% financiación mixta; 100% de las españolas
💶 387M€ presupuesto total estimado

➡ @CDTI_innovacion apoya a los participantes a través de los #NCPs @HorizonteEuropa con simulacros de entrevistas, evaluación de las propuestas y asesoramiento

Más información ➡️https://t.co/2Oj0LiiX3l

#UE #AyudandoCrearFuturo

[CONNECTA Therapeutics @ConnectaThx]

@CDTI_innovacion @CienciaGob @sost_cdti @iPronics @FoodtechMoa @AseBio @ComisionEuropea @LuciaInigo_CDTI @eCasado_CDTI @LGuerra_CDTI 🔝🔝

[CONNECTA Therapeutics @ConnectaThx]

We are honored to announce that @ConnectaThx has been selected for grant and equity funding under the #EICAccelerator from the @EU_EISMEA. The EIC funding will boost our neurodevelopmental clinical developments in #FragileXsyndrome.

[European Innovation Council @EUeic]

New companies selected under EIC Accelerator! 🚀

71 companies have been chosen for funding under #EUeic Accelerator in the most competitive funding round so far since the launch of the Accelerator under Horizon Europe.

Learn more 👉 https://t.co/XxE2EAi5wC

@EZaharievaEU